Wegovy 0.5 mg: the second step in your semaglutide schedule

Why does the Wegovy schedule start so low, and what is 0.5 mg actually for?

Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing how quickly food leaves your stomach and reducing appetite signals. That mechanism is real and meaningful, but it also means your digestive system needs time to settle in. The 0.25 mg dose you take for the first four weeks is purely a tolerability measure; the 0.5 mg dose that follows continues that settling-in process at a modest step up.

Most people find the 0.5 mg period is when they first notice the medicine's effects on appetite, meals feel filling sooner, the urge to snack between them becomes less insistent. These are early signs that semaglutide is working, even though the dose is still well below the maintenance level. The NHS medicines page for semaglutide describes the full titration pathway and what to expect at each stage.

It is worth holding a realistic picture of where 0.5 mg sits in the journey. The clinical trial evidence that established Wegovy's effectiveness (including weight losses averaging around 15% in the STEP 1 study) was built on participants reaching and staying at the 2.4 mg maintenance dose for the full trial period, and if you want to understand how 2 mg Wegovy fits into that progression, the dedicated page walks through what the evidence says at that level. The 0.5 mg phase is scaffolding, not the structure itself. Patience here pays off later. If side effects feel noticeable, that is normal; if they feel severe or persistent, contact your prescriber rather than stopping the injections unilaterally.

What side effects are most common at the 0.5 mg level, and should you be concerned?

Gastrointestinal effects are the most frequently reported reactions during Wegovy titration, and the 0.5 mg step is when many people first encounter them more noticeably than at 0.25 mg. Nausea is the most common; constipation, loose stools, indigestion and burping appear regularly too. Fatigue and headache are reported by some people in the early weeks. The pattern for most is that these effects peak in the first few days after an injection, then ease by the end of the week.

None of that is trivial when you are living through it, but it is also what the slow titration schedule is specifically designed to reduce. Taking your weekly injection on the same day each week, staying well hydrated, eating smaller portions and avoiding very fatty or rich meals during dose increases all help. Injecting on a Friday evening, for example, means any nausea tends to pass before the working week begins, a practical rhythm many people settle into.

There are symptoms that warrant prompt medical attention regardless of how mild they seem on the surface: severe, persistent stomach pain that spreads towards the back (a possible sign of pancreatitis), symptoms of an allergic reaction, or significant dehydration from repeated vomiting or diarrhoea. The MHRA's Yellow Card scheme allows patients to report suspected side effects directly, and doing so contributes to ongoing safety monitoring of these medicines. Any unexpected or worrying symptom should be discussed with your prescriber before your next dose.

How does the 0.5 mg phase connect to the rest of the Wegovy dose schedule?

After four weeks at 0.5 mg, the standard next step is 1.0 mg, and if you want detail on what that increase involves, the page covering Wegovy 1 mg explains what to expect at that stage of titration. The schedule continues from there through 1.7 mg, then 2.4 mg, which was until recently the standard maintenance dose. In January 2026 the MHRA approved 7.2 mg as a higher maintenance option, later supported by a dedicated single-dose pen approved in April 2026, which trials showed achieving around 20.7% average weight loss over 72 weeks. If you want to understand how the full schedule maps out, the complete Wegovy dose guide sets out each level and what the evidence says about it.

Your prescriber will decide whether to move you up to 1 mg after your four weeks at 0.5 mg, or whether to stay a little longer if tolerability has been challenging. That decision belongs to the clinical review, not to the calendar alone. If you are sourcing your treatment through a regulated online pharmacy, every dose change should involve a fresh clinical assessment, that review is a safeguard, not a formality. At nume, a GPhC-registered prescriber personally reads through your check-in before any repeat or dose increase is approved; you can read more about how we work if you want to understand the clinical structure behind the service.

People sometimes ask whether it is safe to stay at 0.5 mg indefinitely if it is well tolerated and producing some results. The honest answer is that the clinical evidence for Wegovy was built on the maintenance dose, and prescribers will generally encourage continued titration unless there is a specific clinical reason to hold. That question is best answered in a proper consultation rather than by inference from a dose page.

Who reaches 0.5 mg, and what does eligibility look like at this stage of treatment?

If you are at the 0.5 mg stage, you have already passed through a clinical assessment and been approved to begin Wegovy. The broader eligibility picture (a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea) was confirmed before you started. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance.

NICE's recommendation for semaglutide (TA875) specifies that it should be used for a maximum of two years within a specialist weight management service, for adults with a BMI of 35 or above (with at least one comorbidity) under NHS commissioning. Private prescribing follows the licensed criteria in the SmPC rather than the NICE commissioning restrictions, which is why a private route through a regulated pharmacy can reach people who do not qualify under the current NHS thresholds or who would face a long wait. The full Wegovy overview covers both NHS and private access routes clearly, including a breakdown of the Wegovy mg options available across the titration schedule.

If you are exploring whether Wegovy is the right choice for your circumstances, or weighing it against tirzepatide (Mounjaro), the weight-loss treatment overview is a useful starting point. Cost is a real consideration too; the Wegovy pricing guide gives an honest picture of what private treatment typically involves. When you are ready to speak to a prescriber, starting a free consultation is the natural next step.